Meridian Bioscience Inc
NASDAQ:VIVO
Meridian Bioscience Inc
Cost of Revenue
Meridian Bioscience Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Meridian Bioscience Inc
NASDAQ:VIVO
|
Cost of Revenue
-$144.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Cooper Companies Inc
NYSE:COO
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-22%
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cost of Revenue
-$491.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-9%
|
See Also
What is Meridian Bioscience Inc's Cost of Revenue?
Cost of Revenue
-144.7m
USD
Based on the financial report for Sep 30, 2022, Meridian Bioscience Inc's Cost of Revenue amounts to -144.7m USD.
What is Meridian Bioscience Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-14%
Over the last year, the Cost of Revenue growth was -24%. The average annual Cost of Revenue growth rates for Meridian Bioscience Inc have been -21% over the past three years , -14% over the past five years .